Researchers at the Massachusetts Institute of Technology have developed a nanoscale particle platform that holds potential as a customizable delivery vehicle for personalized cancer vaccines. The system is built upon a modified, harmless bacteriophage called M13, which forms a nanofiber that can be coated with specific cancer antigens. By precisely controlling the density of these cancer proteins on the particle’s surface, the researchers demonstrated that they could create a vaccine capable of preventing the development of colon tumors in mice. This approach offers a modular framework for designing patient-specific vaccines that target known antigens associated with particular types of cancer.
The backbone of this vaccine technology is the M13 bacteriophage, a virus that is harmless to humans. This virus consists of a single strand of DNA coated in a protein shell, or capsid. For more than two decades, the laboratory of Angela Belcher, the James Mason Crafts Professor of Biological Engineering and Materials Science and Engineering at MIT, has been deploying the M13 bacteriophage in a variety of applications. Belcher has previously developed techniques for generating materials by engineering these viruses to self-assemble into nanoscale scaffolds. By coating these scaffolds with inorganic materials, her team has created functional devices such as batteries, semiconductors, solar cells, and catalysts, with precise control over their electronic, optical, and magnetic properties.
More recently, Belcher’s lab has been developing methods to control specific features of the phage that could allow it to be repurposed for medical applications, including vaccine delivery. The team is taking the toolkit they have worked on and developed over decades and formatting it to be specific for vaccine therapeutics. Some of the lessons learned from making batteries and other electronic components are now being fine-tuned to make personalized vaccines. The capsid that surrounds the M13 phage forms a long filament made from viral proteins. To create vaccines, the researchers modify one of these proteins, known as pVIII, by attaching an antigen to the end of the protein. This modification can be achieved by adding the gene for the antigen to the virus’s DNA.
Previous work from the lab suggested that changing the density of cancer antigens attached to the capsid could affect the strength of the resulting immune response. In the new study, lead author Shengnan Huang, a research scientist at the Koch Institute, sought to find a way to control that density. The antigen serves as the specific target intended to initiate the immune response, which means ensuring the right dose of antigen is critical for generating a strong immune response. Huang discovered that she could increase the density of the modified pVIII proteins by adding one or two negatively charged amino acids to the protein sequence. The density could be further fine-tuned by adding a genetic mutation that slows down the production of the antigen protein.
In this study, the researchers also figured out how to boost the phage’s own ability to act as a vaccine adjuvant by changing the genetic sequence of the virus’s DNA. Most vaccines need to be delivered along with an adjuvant, such as aluminum hydroxide, which helps to stimulate a strong immune response. However, the M13 phage can act as an adjuvant itself because its single-stranded DNA activates a pathway called TLR9, which is part of the body’s innate immune system. This allows the team to control the exact length, antigen expression, density, pattern, and adjuvant amount. A lot of times with a vaccine, you’ll have to put a different adjuvant with it, but now it’s all genetically encoded, according to Belcher.
Using these techniques, the researchers showed that they could design phages that express an antigen called SIINFEKL at densities ranging from 6 percent to 70 percent. SIINFEKL is a small protein that can be engineered into tumors and is often used as a model to test vaccine effectiveness. The researchers tested two of these vaccines in mice, one with 6 percent density and one with 35 percent, and found that the one with 35 percent was the most protective. After vaccination with the higher-density particles, mice were much less likely to develop tumors when later exposed to melanoma cancer cells expressing the SIINFEKL antigen. These mice also generated more T cells targeting SIINFEKL, in part because dendritic cells, which help to activate T cells, were more likely to take up vaccines with higher antigen density.
In another set of experiments, the researchers created and tested a vaccine carrying a neoantigen, which is a protein only present in tumor cells. This protein, known as ADPGK, is specifically expressed by colon tumors in a mouse model of cancer. When given the higher density vaccine, these mice were much less likely to develop colon tumors. In this study, the researchers tested the vaccine as a way to prevent cancer from developing. In their previous work, they had adapted the platform for use to treat mouse colon tumors that have already formed. In the future, they also hope to use it to combat other types of cancer.
The platform could be especially well-suited for personalized cancer vaccines because many different antigens could be swapped into the vaccine. Because this is a modularly engineered platform, the team can change the antigen they are interested in. For colon cancer, they used this specific antigen, but for other types of cancer, they can just plug in other antigens and have them assembled in this platform. The great thing about this is that it’s modular and we could switch out different antigens on demand, so you could design it to be patient-specific and target a known antigen for a particular kind of cancer, Belcher says.
The study appears in the journal Advanced Healthcare Materials. Belcher is the senior author of the study, which was funded in part by the Koch Institute Frontier Research Program, the Marble Center for Cancer Nanomedicine, and the U.S. Defense Advanced Research Projects Agency. Shengnan Huang is the paper’s lead author, and Jack Rudrum, Huaiyao Peng, and Hao Nghi Luu, graduate students at the Koch Institute, are also authors of the paper. The research represents a significant step in the translational potential of the M13 phage platform for cancer immunotherapeutics.
Alberto Danielli, an associate professor of molecular biology at the University of Bologna who was not involved in the study, noted that this interesting work adds another cog to improve the translational potential of the M13 phage platform for cancer immunotherapeutics. He expressed anticipation for seeing whether this platform is also effective against established tumors and whether additional tumor antigens can be displayed with comparable molecular and immunological efficacy.
Subject of Research: Development of a modular M13 bacteriophage nanoparticle platform for delivering personalized cancer vaccines with controlled antigen density
Article Title: MIT engineers create nanoparticles for delivering personalized cancer vaccines
Article References: MIT engineers create nanoparticles for delivering personalized cancer vaccines. Original publication (Bibliographic details unavailable.)
Image Credits: AI Generated
DOI: Not provided
Keywords: cancer vaccines, nanoparticles, M13 bacteriophage, personalized medicine, immunotherapy, antigen density, MIT, Advanced Healthcare Materials, vaccine delivery, neoantigens, engineers, create
News Source: Nathaniel Bowman. (November 10, 2026). MIT engineers design modular bacteriophage nanoparticles for cancer vaccines. Scienmag.



